



Early impact of direct-acting antivirals on chronic HCV prevalence among people who inject drugs in England: real world data, 2011- 2018.

Bardsley M¹, Heinsbroek E¹, Edmundson C¹, Hope V^{1,2}, Hassan N¹, Ijaz S¹, Mandal S¹, Shute J¹, Hutchinson S³, Hickman M⁴, Sinka K¹.

¹ National Infection Service, Public Health England, London, UK. ² Public Health Institute, Liverpool John Moores University, Liverpool, UK. ³ Glasgow Caledonian University, Glasgow, UK. ⁴ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK



Background/aims

- Injecting drug use is cited as a risk factor in 90% of all laboratory reports for HCV infection in England



Background/aims

- Injecting drug use is cited as a risk factor in 90% of all laboratory reports for HCV infection in England
- DAA drugs are transforming the treatment landscape and have been scaled-up in the UK since 2015.



Background/aims

- Injecting drug use is cited as a risk factor in 90% of all laboratory reports for HCV infection in England
- DAA drugs are transforming the treatment landscape and have been scaled-up in the UK since 2015.
- What effect has this had on the chronic HCV prevalence among PWID in England?




T  **GETHER**
FOR ELIMINATION 


Methods

- **UAM**
Survey of
PWID 
Unlinked Anonymous Monitoring Survey
Cross-sectional sentinel surveillance survey of PWID across England, Wales and Northern Ireland.
- Behavioural self-completed questionnaire and dried blood spot sample tested for **HCV antibodies** (measure of ever infection) and **HCV RNA** (marker of current infection)
- **Trends** in chronic infection (HCV Ab- and RNA-positive) **among those ever infected (HCV Ab-positive)**
- Statistical analysis- multivariable logistic regression for risk factors


Results



Results



Results



Conclusions/implications

- Initial results show a small recent reduction in chronic HCV infection among ever infected PWID, concomitant with DAA scale-up
 - risk factors = male gender, injecting in the past year, history of imprisonment and homelessness.
- The proportion of PWID with cleared HCV infection reporting ever receiving treatment for their HCV is at its highest level so far in 2018
- Considerable treatment scale-up is required in order for England to meet the World Health Organisation elimination targets.

Acknowledgements

The UAM team at Public Health England | All the UAM participating sites and participants

Funding: This study is funded by the NIHR Programme Grants for Applied Research programme (Grant Reference Number RP-PG-0616-20008). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

NIHR | National Institute
for Health Research



Public Health
England

UAM
Survey of
PWID



GIG
CYMRU
NHS
WALES

Iechyd Cyhoeddus
Cymru
Public Health
Wales



Public Health
Agency

Megan.Bardsley@phe.gov.uk

Related conference content:

Day 1
09:45-10.00

The Scottish Experience: Reduction in the Population Prevalence of Chronic HCV among People Who Inject Drugs Associated with Major Scale-Up of Direct-Acting Antiviral Therapy in Community Drug Services: Real World Data.

Norah Palmateer, Glasgow Caledonian University

Poster #003

Hepatitis C Testing And Access To Care Among People Who Inject Psychoactive Drugs In England, Wales And Northern Ireland: Insights From 2017 National Survey Data.

Claire Edmundson, Public Health England

Poster #004

The Association Between Homelessness And Hepatitis C Exposure Among 11,101 People Who Inject Drugs In England, Wales And Northern Ireland: A Cross-sectional Study.

Binta Sultan, University College London, England.